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Abstract Demonstration of the absence of neurovirulent
properties of reassortant viruses contained in live attenu-
ated influenza vaccine (LAIV) is a regulatory requirement.
A mouse model was used to detect neurovirulent properties
of the cold-adapted, temperature-sensitive and attenuated
influenza master donor viruses (MDVs) A/Leningrad/134/
17/57 (H2N2) and B/USSR/60/69 and derived reassortant
influenza viruses. A/NWS/33 (H1N1), which is known to
be neurovirulent in mice, was used as a positive control.
Under conditions where the positive control virus induced
symptoms of disease and showed viral replication in the
upper respiratory tract as well as in the brain, replication of
the influenza master donor viruses and reassortant influenza
A and B viruses was limited to the upper respiratory tract
where they were administered. None of the mice inoculated
with MDVs or reassortant influenza viruses suffered from
disease, and no virus or viral replication was observed in
the brains of these mice. The results demonstrate the
absence of neurovirulent properties of the MDVs and
reassortant influenza viruses derived therefrom used in
LAIV.
Introduction
Influenza virus infection has been associated with several
neurological disorders, including febrile seizures, influenza
encephalopathy, post-influenza encephalitis, post-enceph-
alitic Parkinson’s disease, Guillain Barre´ syndrome,
Kleine–Levin syndrome and Reye’s syndrome [6, 20].
Clinical outcomes of these diseases are highly variable and
may range from complete recovery without sequelae to
severe neurological dysfunction or death. These diseases,
however, are rare, and their aetiology and pathogenesis are
still largely unknown [6, 11, 20].
Though neurological disease is rarely seen upon influ-
enza virus infection, neurovirulence is a concern with live
virus vaccines. It is for this reason that regulatory author-
ities require that the absence of neurovirulent properties of
viruses used in live attenuated influenza vaccine (LAIV) be
demonstrated [2]. Neurovirulence of influenza virus, which
has been defined as the ability to undergo multicycle rep-
lication in the brain, has been studied in mice, using the
neurovirulent A/NWS/33 (H1N1) virus [18, 22]. The
availability of this virus as a positive control virus makes
mice an attractive animal model to study neurovirulent
properties of other influenza viruses, in particular those
used in LAIV.
The master donor viruses A/Leningrad/134/17/57
(H2N2) and B/USSR/60/69, which are the basis of LAIV,
were obtained by repeated passages in embryonated
chicken eggs at low temperature (25–26C), which ren-
dered them cold-adapted (ca), temperature-sensitive (ts)
and attenuated (att) [1, 8, 10]. These master donor viruses
are used to generate reassortant influenza viruses that
contain the surface glycoproteins haemagglutinin and
neuraminidase of currently circulating influenza viruses,
while the ca/ts/att phenotype is inherited from the master
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donor virus. A combination of influenza A H1N1 and
H3N2 reassortant viruses and an influenza B reassortant
virus are used in LAIV. The ca phenotype enables these
viruses to replicate relatively efficiently at low tempera-
tures, while the ts phenotype limits replication at high
temperatures. Following intranasal administration of
LAIV, viral replication will primarily take place in the
nasopharynx of the upper respiratory tract, where lower
temperatures prevail, while replication becomes restricted
in the relatively warmer lower respiratory tract.
In the present paper, we confirmed that A/NWS/33
(H1N1) is a suitable positive control virus to detect neu-
rovirulent properties in mice. Using the mouse model,
neurovirulent properties of the influenza master donor
viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69
as well as reassortant influenza A and B viruses derived
therefrom were studied.
Materials and methods
Animals, cells and viruses
In all studies, female Swiss mice at the age of 4–6 weeks
were used. Madin Darby canine kidney (MDCK) cells
and A/NWS/33 (H1N1) were obtained from the American
type culture collection (ATCC). Master donor viruses
A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 were
originally obtained from the Institute of Experimental
Medicine, St. Petersburg, Russia. Wild-type viruses
A/Brisbane/59/07 (H1N1), A/Brisbane/10/07 (H3N2),
B/Brisbane/3/07 and B/Brisbane/60/08 were obtained from
the National Institute for Biological Standards and Control
(NIBSC), UK. 6:2 reassortant influenza viruses were
obtained by co-infection of MDCK cells or embryonated
chicken eggs with master donor virus and wild-type virus.
Viruses were amplified either in MDCK cells or embryo-
nated chicken eggs.
Neurovirulence studies
Prior to conducting animal studies, approval was obtained
from the animal experimentation committee. Anesthetized
mice (ten per group) were inoculated either intracerebrally
with 30 ll or intranasally with 50 ll of A/NWS/33
(H1N1), A/Leningrad/134/17/57 (H2N2) (referred to as
MDV A), or B/USSR/60/69 (referred to as MDV B) at
titers varying from 3 to 8 log10 TCID50/ml or non-infected
allantoic fluid as a negative control. Five days after inoc-
ulation, five mice per group were euthanized by intraperi-
toneal injection of 150 ll dolethal, and their brains were
collected. Brains were split into two portions: one half was
collected in shredder tubes with ceramic beads in 500 ll
PBS containing antibiotics, antimycotics and 4% (w/v)
sucrose, ground and kept at -70C until used for virus
detection by PCR and titration; the other half was collected
in 4% (v/v) formaldehyde solution for histopathology. At
day 14, the remaining surviving mice were euthanized, and
their brains were analyzed as above. If mice were found
dead during the study, their brains were collected on that
day, if possible. To avoid unnecessary suffering, some
mice were euthanized, and their brains were collected on
non-projected days. Non-projected days are days before
day 5 or days between days 5 and 14.
In another study, ten mice per group were inoculated
intranasally with 50 ll live A/NWS/33, live MDV A or
MDV B at a titer of 6.7 ± 0.5 log10 TCID50/ml, or with
50 ll beta-propiolactone (BPL)-inactivated MDV A or
MDV B or PBS as a negative control. Virus inactivation
was confirmed by titration. Three days post-inoculation,
nasal turbinates and brains were collected for virus detec-
tion by PCR and titration.
In three good laboratory practice (GLP) studies, groups
of 40 mice were used, and 50 ll of virus at a titer of
7.0 ± 0.5 log10 TCID50/ml was administered intranasally.
Ten mice per group were sacrificed 3 days post-inocula-
tion, and nasal lavages and turbinates were collected for
virus titration. These mice served as controls to detect
whether virus replication in the upper respiratory tract had
taken place. The remaining 30 mice per group were
euthanized 5 days post-inoculation, and their brains were
collected for virus titration.
Clinical symptoms
Mice were observed daily for clinical symptoms. General
symptoms of distress (piloerection, hunched posture,
weight loss and reduced physical activity) as well as neu-
rological symptoms (paresis and paralysis) were recorded.
Symptoms were classified as mild if only one general
symptom of distress was observed, moderate if more than
one of these symptoms was observed and severe if mice
either suffered from neurological symptoms, were found
dead or were euthanized because of the seriousness of the
symptoms.
RNA isolation, cDNA synthesis and PCR
RNA of 70 ll tissue homogenate was isolated according to
the manufacturer’s instructions (QiaAmp Viral RNA Kit,
Qiagen). Seven microliter of RNA was used to synthesize
cDNA according to the manufacturer’s instructions
(Quantitect Reverse Transcription Kit, Qiagen) using the
forward primers described below. For PCR, 6 ll cDNA
template was used in a total reaction volume of 50 ll PCR
buffer containing 2 ll of 100 pmol solutions of forward
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and reverse influenza nucleoprotein-specific primers
(Influenza A: 50-CAAAACAGCCAAGTATACAGCC
[forward] and 50-AGTAGAAACAAGGGTATTTTTCCTT
AAT [reverse], Influenza B: 50-CCCAGAAGATCAGGT
GCAACTG [forward] and 50-TGCTTGCTTAGAGCAAT
AGGTC [reverse]), 5 ll of a 2 mM solution of dNTPs and
1 ll of a 1 unit/ll solution of SuperTaq polymerase. PCR
conditions were as follows: 4 min at 94C followed by 30
cycles of 30 s at 94C, 1 min at 50C and 2 min at 68C
and a final elongation step of 7 min at 68C. RNA isolated
from A/NWS/33 (H1N1), MDV A and MDV B was used to
prepare cDNA, which served as positive controls in the
PCR. Negative PCR controls consisted of PCR reaction
mixtures without template cDNA.
Titrations
Tissue homogenates were titrated on MDCK cells. Briefly,
serial dilutions of tissue homogenates were inoculated on
MDCK cells and incubated for 6 days at 32C and 5%
CO2, followed by measurement of haemagglutination of
0.5% (v/v) chicken or 1% (v/v) guinea pig red blood cells
added to tissue culture supernatants. The titer was calcu-
lated according Reed and Muench [16] and expressed as
log10 TCID50/ml.
Histopathology
Tissue specimens of the brains were used to detect histo-
pathological changes. Histopathological examination of the
brains was classified as showing meningeal lymphocytic
infiltration, perivascular mononuclear cuffing, gliosis and
necrotic foci associated with Gitter cells and were graded
as absent (0), minimal (1), slight (2) or moderate (3).
Results
A/NWS/33 (H1N1) has been demonstrated in the past to be
neurovirulent in mice and therefore could be a suitable
positive control virus to detect neurovirulent properties of
other influenza viruses [22]. To confirm the neurovirulent
properties of A/NWS/33 (H1N1) and to determine the dose
to be used as a positive control, mice were inoculated
intracerebrally or intranasally with different doses of
A/NWS/33 (H1N1). It was shown that, following intrace-
rebral inoculation at a dose of 5.5 log10 TCID50 or higher,
virus could be detected in the brain and induced symptoms
of disease as well as histopathological changes within
5 days (Table 1). No virus could be detected by PCR in the
brain of mice euthanized at day 14, demonstrating that the
virus was cleared in 14 days. Between days 5 and 14, one
mouse in the 1.5 log10 TCID50/dose group and one mouse
in the 5.5 log10 TCID50/dose group were euthanized
because of the seriousness of the symptoms and only the
brains of these mice, like those euthanized at day 5, were
found to be positive by PCR. Following intranasal inocu-
lation, virus could be detected in the brains at day 5 in a
minority of mice, and no virus was detected at day 14.
Between days 5 and 14, four mice in the 3.7 log10 TCID50/
dose group, 2 mice in the 5.7 log10 TCID50/dose group and
one mouse in the in the 6.7 log10 TCID50/dose group died
or were euthanized because of the seriousness of the
symptoms, and the brains of these mice were found to be
positive by PCR. Histopathological changes in the brain
were on average less clear for mice inoculated intranasally
than those inoculated intracerebrally. In contrast, symp-
toms of disease seemed more pronounced but appeared at a
later stage in mice inoculated intranasally than those
inoculated intracerebrally, and macroscopy of the lungs of
mice inoculated intranasally (3.7 TCID50/dose and higher)
revealed significant lung lesions, whereas virtually no
changes in the lungs were observed for mice inoculated
intracerebrally (data not shown). Together, these results
show that A/NWS/33 (H1N1) is both a pneumo- and
neurotropic virus that can be detected in the brains of mice
inoculated either via the intracerebral or intranasal route,
confirming the usefulness of this virus as a positive control
to detect neurovirulent properties.
To demonstrate that both MDV A and MDV B can
replicate in mice, and to demonstrate that live virus is
needed to obtain positive PCR and titration results, mice
were inoculated intranasally with either live or inactivated
MDV A or MDV B as well as with A/NWS/33 (H1N1) and
PBS as positive and negative controls, respectively. Since
the optimum day of replication of influenza viruses after
intranasal administration is typically day 3, nasal turbinates
were collected at that day to detect whether viral replication
had taken place. To determine whether viral replication
could already be detected in the brain of the positive control
on that same day (in the previous study this was only
measured at day 5), brains were also isolated and subjected
to PCR and titration. The results show that inactivated
viruses did not yield positive PCRs in the brain or in the
upper respiratory tract (URT), whereas live viruses were
positive by PCR in the URT (Table 2). With the exception
of one mouse, which showed a low titer for inactivated
MDV B in the URT, none of the mice that were inoculated
with inactivated virus had detectable virus titers in their
brains or URT, whereas the majority of mice that were
inoculated with live virus did show detectable virus titers in
the URT. The sample from the mouse that was found to be
weakly positive in titration most likely was contaminated
with live MDV B during titration, since the inactivated
MDV B used for inoculation was confirmed to be negative
in titration and because PCR conducted on the same sample
Neurovirulence of live attenuated influenza vaccine 1393
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Table 1 Neurovirulent properties of A/NWS/33 (H1N1)
Titer (log10 TCID50/dose)
and route of inoculationa
Days post-
inoculation
PCR-positive
brains
Clinical symptomsb Histopathologyc
None Mild Moderate Severe A B C D
0 i.c. (neg. control) 0–5 - 5/5 - - - 0 0 0 0
6–14 - 5/5 - - - 0 0 0 0
1.5 i.c. 0–5 - 5/5 - - - 0 0 0 0
6–14 1/5d 2/5 1/5 1/5 1/5 1 0 2 3
3.5 i.c. 0–5 3/5 3/5 2/5 - - 3 3 1 2
6–14 - 5/5 - - - 0 1 2 0
5.5 i.c. 0–5 5/5 - - 2/5 3/5 (2) 3 2 2 2
6–14 1/5d 4/5 - - 1/5 2 0 2 3
6.5 i.c. 0–5 8/8 - 1/8 4/8 3/8 (3) 2 2 2 2
6–14 - - 1/2 1/2 - 1 0 1 3
0 i.n. (neg. control) 0–5 - 5/5 - - - 0 0 0 0
6–14 - 5/5 - - - 0 0 0 0
1.7 i.n. 0–5 - 5/5 - - - 0 0 0 0
6–14 - 5/5 - – - 0 0 0 0
3.7 i.n. 0–5 2/5 5/5 - - - 1 1 0 0
6–14 4/5d - 1/5 - 4/5 (2) 2 0 2 0
5.7 i.n. 0–5 - - - 4/5 1/5 (1) 0 0 0 0
6–14 2/5d - - 1/5 4/5 (2) 1 1 2 0
6.7 i.n. 0–5 1/6 - - 3/6 3/6 (3) 1 2 2 0
6–14 1/4d - 1/4 1/4 2/4 (1) 3 2 2 0
-, negative or none
a i.c., intracerebral; i.n., intranasal
b Symptoms are classified as None, no clinical symptoms; Mild, one of the following general symptoms of distress: piloerection, hunched
posture, weight loss, reduced physical activity, Moderate, more than one of the previous symptoms; Severe, neurological symptoms (paresis or
paralysis), death or euthanization because of seriousness of symptoms. The number of dead mice is shown in brackets
c Histopathology is classified as A. Meningal lymphocytic infiltration, B. Perivascular mononuclear cuffing, C. Gliosis, D. Necrotic foci
associated with gitter cells with the following grades: 0: absent, 1: minimal, 2: slight and 3: moderate
d Mice that died or were euthanized because of symptoms on non-projected dates
Table 2 Replication of influenza A and B viruses in mice
Inoculuma Virus detection
URT day 3 p.i.b Brains day 3 p.i.
PCR no. pos. Titration no. pos. Mean titerc PCR no. pos. Titration no. pos. Mean titerc
A/NWS/33 (H1N1) live 5/5 5/5 6.0 - - na
MDV A live 5/5 3/5 3.5 - - na
MDV A inactivated - - na - - na
MDV B live 4/5 5/5 4.7 - - na
MDV B inactivated - 1/5 2.1 - - na
Negative control - - na - - na
-, negative; na, not applicable
a Inocula administered intranasally at an infectious titer of 5.4 ± 0.5 log10 TCID50/dose; infectious titers of inactivated viruses were confirmed
to be negative
b URT, upper respiratory tract; p.i, post-incoculation
c Mean titer of positive samples expressed as log10 TCID50/ml
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was also negative. Thus, both MDV A and MDV B do
replicate in the URT of mice, which is needed to obtain
positive PCR and titration results. From this experiment, it
is also clear that day 3 is too early to detect viral replication
in the brain following intranasal administration. None of the
mice inoculated with A/NWS/33 (H1N1) showed any
positive PCR or titration results in their brains at day 3.
After having demonstrated that both master donor
viruses were able to replicate in mice, neurovirulent
properties of the MDVs were studied using A/NWS/33
(H1N1) as a positive control. Mice inoculated intracere-
brally with A/NWS/33 (H1N1) showed symptoms and
histopathological changes in their brains (Table 3). Virus
could be detected by PCR in the brains of 4 out of 5 mice,
and infectious titers were measured in the brains of all mice
at day 5. An example of PCR analysis is shown in Fig. 1.
Like in the first study, no virus could be detected by PCR
or titration at day 14. The only mouse that was PCR and
titration-positive beyond day 5 was one that was found
dead on day 6. Mice inoculated intracerebrally with MDV
A or MDV B showed only mild symptoms and minimal
histopathological changes, if any at all. Moreover, no virus
could be detected in the brains by PCR or titration, dem-
onstrating that the master donor viruses were cleared
within 5 days of inoculation and were not able to reside or
replicate in the brain. Following intranasal inoculation with
A/NWS/33 (H1N1), the same pattern was observed as in
the first study: clinical symptoms were more pronounced
and appeared later in time than those of mice inoculated
intracerebrally. Histopathogical changes of the brain were
virtually absent in mice inoculated intranasally, but
macroscopy of the lungs revealed significant lesions in this
group (data not shown). In contrast to the first study, this
time, virus could be detected by PCR at day 5 in the brains
of all mice that were inoculated intranasally. With the
exception of one mouse showing mild symptoms and
minimal histopathological changes following intranasal
inoculation with MDV A, none of the mice inoculated
intranasally with MDV A or B showed clinical symptoms
or histopathological changes. No virus could be detected in
the brains of any of these mice, either by PCR or by
titration, demonstrating that these viruses do not reach the
brain after intranasal administration.
From the above studies, it is clear that it is not useful to
analyze brains at day 14, as no virus can be detected
anymore by that time. While day 14 is far too late, day 3 is
too early to detect virus in the brain. Day 5 has been shown
to be a good time point for measurement, as live virus can
be detected in the brain by that time and, to prevent
unnecessary suffering, is the most suitable day for eutha-
nasia. Since live virus could be detected in the brain of
control mice after intranasal inoculation, and because the
route of vaccination of LAIV is intranasal, subsequent
studies only used the intranasal route and included sub-
groups of mice that were sacrificed at day 3 to detect viral
replication in the upper respiratory tract.
In the first of three studies conducted in accordance with
GLP, it was shown that both MDV A and MDV B did
Table 3 Neurovirulent properties of influenza A and B master donor viruses
Inoculum and route
of inoculationa
Days post-
inoculation
PCR-positive
brains
Titration-positive
brains
Clinical symptomsb Histopathologyc
None Mild Moderate Severe A B C D
A/NWS/33 (H1N1) i.c. 0–5 4/5 5/5 - 2/5 2/5 1/5 (1) 2 2 3 3
6–14 1/5d 1/5d - 1/5 3/5 1/5 (1) 1 2 1 1
MDV A i.c. 0–5 - - 5/5 - - - 1 1 0 0
6–14 - - 3/5 2/5 - - 0 0 0 0
MDV B i.c. 0–5 - - 5/5 - - - 0 1 0 0
6–14 - - 5/5 - - - 0 0 0 0
A/NWS/33 (H1N1) i.n. 0–5 5/5 4/5 5/5 - - - 1 0 0 0
6–14 2/5d 1/5d - - 1/5 4/5 (3) 0 0 0 0
MDV A i.n. 0–5 - - 5/5 - - - 0 0 0 0
6–14 - - 4/5 1/5 - - 1 0 0 0
MDV B i.n. 0–5 - - 5/5 - - - 0 0 0 0
6–14 - - 5/5 - - - 0 0 0 0
-, negative or none
a Inocula adminstered intracerebrally (i.c.) or intranasally (i.n.) at infectious titers of 5.5 log10 TCID50/dose or 5.7 log10 TCID50/dose,
respectively
b See Table 1 for classification of symptoms. The number of dead mice is shown in brackets
c See Table 1 for classification of histopathology
d Mice that died or were euthanized because of symptoms on non-projected dates
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replicate in the upper respiratory tract but were unable to
spread to the brain (Table 4). In contrast, A/NWS/33
(H1N1) spread to and replicated in the brains of the
majority of the mice after intranasal administration. While
A/NWS/33 (H1N1) induced symptoms of disease, none of
the master donor viruses did. In the second GLP study, 6:2
reassortant influenza viruses of the flu season 2008–2009
were generated (A44/Brisbane/59/07 (H1N1), A44/Bris-
bane/10/07 (H3N2) and B56/Brisbane/3/07). It was dem-
onstrated that these reassortant viruses are able to replicate
in the upper respiratory tract. In contrast to mice inoculated
with A/NWS/33 (H1N1), mice inoculated with 6:2 reas-
sortant influenza viruses showed virtually no symptoms of
disease and did not show infectious titers in their brains. In
this experiment, the number of mice that showed replica-
tion and the virus titers that were obtained for the influenza
A reassortant viruses were low, as were the number of
positives and titers obtained in the brains of mice inocu-
lated with A/NWS/33 (H1N1). In the third GLP study, a
new 6:2 reassortant virus (B56/Brisbane/60/08) based on
MDV B was studied. Again, virus replication was dem-
onstrated in the upper respiratory tract, with virtually no
symptoms, and again, no virus was measured in the brain,
whereas A/NWS/33 (H1N1) replicated both in the upper
respiratory tract and in the brain and also induced symp-
toms of disease. These three studies clearly demonstrate
that both MDV A and MDV B as well as reassortants
derived therefrom are unable to reach and replicate in the
brain following intranasal administration.
Fig. 1 Example of PCR analysis of brain homogenates. Left panel
mice inoculated intracerebrally (i.c.) or intranasally (i.n.) with
A/NWS/33, MDV A or MDV B. Right panel positive (A/NWS/33,
MDV A and MDV B) and negative PCR controls
Table 4 Good laboratory practice (GLP) studies to detect neurovirulent properties of master donor viruses and reassortant viruses
Inoculuma Virus replication Clinical symptomsc
URT day 3 p.i.b Brains day 5 p.i.
No pos. Mean titerd No. pos. Mean titerd None Mild Moderate Severe
GLP study 1
A/NWS/33 (H1N1) 10/10 5.8 25/29 3.4 - 16/30 7/30 7/30 (7)
MDV A 4/10 3.0 - - 30/30 - - -
MDV B 10/10 5.8 - - 29/29 - - -
Negative control - - - - 29/29 - - -
GLP study 2
A/NWS/33 (H1N1) 10/10 [5.0 13/30 2.5 1/30 8/30 14/30 7/30 (7)
A44/Brisbane/59/07 (H1N1)e 4/10 2.4 - - 29/30 1/30 - -
A44/Brisbane/10/07 (H3N2)e 2/10 2.2 - - 30/30 - - -
B56/Brisbane/3/07e 10/10 3.5 - - 30/30 - - -
Negative control - - nd na 30/30 - - -
GLP study 3
A/NWS/33 (H1N1) 10/10 5.9 25/30 3.2 - 6/30 18/30 6/30 (6)
B56/Brisbane/60/08e 9/10 4.6 - - 29/30 1/30 - -
Negative control - - nd na 30/30 - - -
-, negative or none; na, not applicable; nd, not done
a Inocula administered intranasally at an infectious titer of 5.7 ± 0.5 log10 TCID50/dose
b URT, upper respiratory tract; p.i, post-inoculation
c See Table 1 for classification of symptoms. The number of dead mice is shown in brackets
d Mean titer of positive samples expressed as log10 TCID50/ml
e Reassortant virus based on master donor virus
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Discussion
Demonstration of the absence of neurovirulent properties
of viruses contained in LAIV is a requirement by regula-
tory authorities [2]. While mice, ferrets and monkeys are
the most frequently used models in influenza virology,
historically, monkeys have been used to study neuroviru-
lence. According the European Pharmacopoeia the brains
of monkeys are to be inoculated with virus to be tested,
followed by observation of the animals for neurological
symptoms and histopathological analysis of the brain at the
end of the observation period. This model lacks a positive
control virus, and there is no need to demonstrate the
presence of virus or viral replication in the brain following
inoculation. The mouse model offers several advantages in
studying neurovirulent properties of influenza viruses. In
contrast to ferrets and monkeys, mice are easy to handle
and accommodate and allow for big group sizes. Ferrets
and monkeys are not easily available in sufficient numbers,
and there are ethical objections against using monkeys
when other animal models are available. The most
important advantage of mice, however, is the availability of
a positive control virus such as A/NWS/33 (H1N1) that
replicates in the brain of mice [22]. For ferrets and mon-
keys, a positive control would need to be sought that is
potentially highly pathogenic to humans. Indeed, highly
pathogenic H5N1 strains have been shown to be neuro-
virulent in ferrets [4, 5, 12, 23], whereas the recent novel,
and less pathogenic, H1N1 virus is not [15]. To the best of
our knowledge, there are no reports available of influenza
viruses invading and replicating in the brain of monkeys,
but if such a virus was available, it most likely would be
highly pathogenic to humans. Thus, the mouse model is
preferable from a safety, ethical and practical point of
view. In addition, the use of small-animal models is also
encouraged by regulatory authorities [2].
We studied neurovirulent properties of the ca, ts and att
master donor viruses A/Leningrad/134/17/57 (H2N2)
(MDV A) and B/USSR/60/69 (MDV B) as well as ca/ts/att
reassortant influenza A and B viruses derived from them in
a mouse model using A/NWS/33 (H1N1) as a positive
control virus. Summarizing all of the studies, in none of the
mice inoculated intranasally with MDV A, MDV B or re-
assortant influenza A and B viruses, could virus be detected
in the brain 5 days post-inoculation, whereas in the
majority of mice inoculated with A/NWS/33 (H1N1), the
presence of virus and viral replication in the brain was
demonstrated. We did not isolate brains of mice inoculated
intranasally with master donor viruses or derived reassor-
tants between days 5 and 14. Although, based on the data,
it cannot be excluded that master donor viruses or reas-
sortants may reach the brain between days 5 and 14, it is
highly unlikely that they replicate in the brain. In support
of this, master donor viruses inoculated directly into the
brain could not be detected anymore at day 5. Furthermore,
if master donor viruses or reassortants were able to repli-
cate in the brain (i.e., were neurovirulent), this most likely
would be noticed due to the appearance of clinical symp-
toms. None of the mice inoculated either intracerebrally or
intranasally suffered from disease, whereas mice inocu-
lated with A/NWS/33 (H1N1) clearly did. Thus, neither the
master donor viruses nor the reassortants derived from
them displayed neurovirulent properties in this mouse
model.
For mice inoculated intranasally, there seemed to be no
relationship between the dose of A/NWS/33 (H1N1)
administered and the number of mice that were found
virus-positive in the brain in the first experiment. In mice
receiving the highest doses (including 5.7 log10 TCID50/
dose), fewer virus-positive brains were found compared to
mice receiving a lower dose. It is not clear where the
variation seen in the first experiment comes from. How-
ever, in subsequent experiments, virus could be detected
and viral replication demonstrated in the brains of the
majority of mice inoculated with approximately 5.7 log10
TCID50/dose.
While for MDV B and reassortant influenza B viruses,
viral replication in the upper respiratory tract could be
clearly demonstrated in the vast majority of mice, for MDV
A and reassortant influenza A viruses, both the number of
mice that showed viral replication in the upper respiratory
tract and the viral titers obtained were relatively low, most
notably in GLP study 2. While procedural imperfections
cannot be ruled out for this particular study (the number of
positive brains and the titers of control virus were also
relatively low), it appears that the mice used are less sus-
ceptible to MDV A and influenza A reassortants compared
to MDV B and influenza B reassortants. This is explained
by the fact that mice are not natural hosts for influenza
virus, and seasonal influenza viruses usually need prior
adaptation to yield high titers [21]. Results may improve
when another breed of mice is used or when the doses
administered are increased. Nevertheless, viral replication
in the upper respiratory tract, in the absence of clinical
signs, has been demonstrated for the master donor viruses
and reassortant viruses derived from them, which supports
the usefulness of this animal model.
The influenza viruses contained in LAIV have a ca/ts/att
phenotype. The ca/ts/att influenza viruses A/Leningrad/
134/17/57 (H2N2) and B/USSR/60/69 were generated
previously in Russia, and these strains are currently in use
as master donor viruses to generate reassortant influenza A
and B viruses containing the surface glycoproteins hae-
magglutinin and neuraminidase of currently circulating
strains, whilst the gene segments conferring the ca/ts/att
phenotype are inherited from the master donor virus
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(so-called 6:2 reassortants). In light of this phenotype, the
need for neurovirulence studies could be questioned for the
influenza viruses contained in LAIV. Indeed, these viruses
will be restricted in their replication outside the upper
respiratory tract. The ca/ts/att phenotype results from
multiple mutations, and loss of attenuation would require
reversion of multiple mutations, which is unlikely to occur
in vivo [9] or in vitro. Indeed, we have demonstrated that
these mutations are conserved after 15 successive passages
of both master donor viruses (unpublished data). The
genome composition, the presence of mutations and tem-
perature sensitivity are confirmed for each virus strain prior
to their use in LAIV. In addition, while the surface gly-
coproteins haemagglutinin (HA) and neuraminidase (NA)
have been shown to be involved in neurovirulence of
mouse-adapted strains, other genes may play a role as well
[22]. The master donor virus A/Leningrad/134/17/57
(H2N2) was isolated during the 1957 pandemic. In contrast
to the pandemic of 1918, which has been associated with
encephalitis lethargica, the pandemics of 1957 and 1968
have not been associated with neurological disease [13].
Furthermore, vaccine strains are always 6:2 reassortants,
and therefore any additional role of the genes coding for
internal viral proteins is excluded. Finally, ample experi-
ence with LAIV in Russia ([30 9 106 doses) using
numerous different 6:2 reassortant strains has not revealed
any vaccine-related neurological disease.
Despite the observed temporal and/or geographical
association of influenza epidemics with neurological dis-
ease, it remains to be demonstrated that influenza virus is a
direct cause. For example, influenza virus or viral antigens
are rarely demonstrated in the cerebrospinal fluid or brain
of patients suffering from influenza encephalopathy [7, 14,
19]. In addition, Guillain Barre´, Kleine–Levin and Reye’s
syndrome all are associated with infections not necessarily
involving influenza virus, and, in the case of Reye’s syn-
drome, the role of viral infection, if there is any, may be
limited [3, 17]. It appears that invasion and replication of
influenza virus in the central nervous system (CNS) is not
the primary cause of influenza-associated neurological
disease but that infection with viruses may occasionally
induce excessive immunological and physiological
responses leading to neurological disorders. Indeed,
hypercytokinemia has been suggested to be involved in the
pathogenesis of influenza encephalopathy [11, 14, 19]. The
fact that influenza-associated encephalopathy was observed
in Japan, but not elsewhere, during an H3N2 epidemic may
be explained by a genetic component that predisposes an
individual for hypercytokinemia [14]. This supports the
idea that not neuroinvasion, but the response to infection
plays a primary role in influenza-associated encephalopa-
thy. Hypercytokinemia has not been reported for LAIV.
Thus, for strains contained in LAIV to be neurovirulent
and cause neurological disease, a combination of properties
and events is required. First, the wild-type influenza strain
used in reassortment must have neurovirulent properties,
allowing the virus to reach and replicate in the CNS, which
is rare for seasonal human influenza. Second, NA and/or
HA alone must play a decisive role in neurovirulence.
Third, the resulting neurovirulent 6:2 reassortant, which
has been checked phenotypically and genotypically, must
reverse multiple mutations in vivo to lose its temperature-
sensitive and attenuated phenotype to allow for spread and
replication outside the upper respiratory tract, which is
highly unlikely. The concurrence of these properties and
events during seasonal influenza vaccination with LAIV is
negligible.
In conclusion, the mouse model has been demonstrated
to be useful for studying neurovirulence. Although the
chances on neuroinvasion and subsequent neurological
disease may be considered negligible for viruses contained
in LAIV, the absence of neurovirulent properties can be
demonstrated using the mouse model.
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